Roberto De Luca | Senior Scientist
Philochem AG

Roberto De Luca, Senior Scientist, Philochem AG

Roberto De Luca graduated in Biology at ETH Zürich. He performed his PhD studies at ETH Zürich focusing on the generation of antibody-cytokine fusion proteins for the treatment of tumors. Dr. De Luca is author of several peer-reviewed publications in international scientific journals.

Appearances:



Festival of Biologics Day 2 @ 17:20

Tripokin: tumor targeted delivery of IL2 potentiated by TN

  • Tripokinis an antibody fusion protein featuring both IL2 and TNF in one product
  • IL2 and TNF have a synergistic mechanism of action
  • Tripokinshows a strong anti-cancer activity in mouse models of cancer both as single agent andin combination with immune check-point inhibitors
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT
last published: 17/Sep/21 16:05 GMT

back to speakers